Pharma, biotech and life science disputes

This is one of our nuclear areas of expertise.  Professor Hanna Roos has conducted over a decade of research into the intersection of medicine and law with the University of Cambridge.  She  lectures as External Professor at the Mario Negri Institute, Italy, on the funding of expensive treatment that can save children’s lives, and has been called “one of the most impressive thinkers of her generation” for this work.

We do not have a transactional practice that acts for pharma, biotech and life sciences companies.  We can therefore act freely for all players in this ecosystem.

Our expertise involves:

  • Leading a forensic investigation into irregular conduct of employees of a multinational pharmaceutical services company, including providing data privacy advice, to minimise likelihood of contentious follow-on proceedings.
  • Representing Allergan as third party in the Auden McKenzie (Pharma Division) Ltd & Ors v Patel & Anor fraud claim before the High Court.
  • Advising an Asian biopharmaceutical company regarding research tool patents and license agreements.
  • Advising an Asian biopharmaceutical company regarding joint venture and related agreements.
  • Advising pharmaceutical company in a potential dispute regarding commercialisation and marketing authorisation of a novel treatment in Europe.